What are CD19 levels in multiple sclerosis (MS) and how are they used clinically?

CD19 Levels in Multiple Sclerosis

CD19+ B cells are not routinely measured for MS diagnosis or monitoring in standard clinical practice, but they serve as critical biomarkers for monitoring B-cell depleting therapies and understanding disease pathophysiology.

What Are CD19 Levels in MS?

CD19 is a surface marker expressed on B cells throughout their development (except on plasma cells). In MS patients:

Cerebrospinal Fluid (CSF)

• CD19+ B cells comprise 2-11% (mean 5%) of total CSF lymphocytes in clinically definite MS 1
• African American MS patients show higher proportions of CD19+ cells in CSF (5.46%) compared to White patients (2.26%) 2
• CD19+ B cells are increased in bout-onset MS compared to primary progressive MS and other neurological diseases 3
• CSF shows higher proportions of CD19+ cells compared to peripheral blood, indicating compartmentalized inflammation 4

Peripheral Blood

• In untreated MS patients, circulating CD19+ B-cell counts do not significantly differ from healthy controls 4
• Baseline CD19+ B-cell counts are highly variable between individuals 5, 6

Clinical Applications

1. Monitoring B-Cell Depleting Therapies

This is the primary clinical use of CD19 measurement in MS.

With Ocrelizumab/Rituximab Treatment:

Baseline CD19 counts predict repopulation kinetics:

• Patients with higher baseline CD19 counts show faster B-cell repopulation after treatment 6
• Fast repopulators (26-45% of patients) have significantly higher MRI activity at 12 months (17.39% vs 2.53% active scans) 6

Monitoring schedule:

• Measure CD19+ B cells every 6 months during treatment 5, 6
• Low or absent CD19+ B-cell counts correlate with reduced annualized relapse rate, EDSS scores, and gadolinium-enhancing MRI lesions 5
• Repopulation intervals vary widely: mean 9.73 months, but highly individualized (range from months to >1 year) 5

Treatment adjustment strategy:

• Patients with complete CD19 depletion can extend infusion intervals beyond the standard 6-month schedule 5
• Fast repopulators may require more frequent dosing or higher doses to maintain disease control 6
• Consider tailoring ocrelizumab dosage based on baseline CD19 counts to achieve complete depletion in all patients 6

2. Residual B Cells After Anti-CD20 Therapy

Important caveat: Anti-CD20 therapy does not deplete all B cells equally:

• CD11c+ atypical B cells and plasmablasts are less efficiently depleted and comprise higher proportions of remaining B cells 4
• CD138+ plasma cells (which lack CD19) are not targeted by anti-CD20 therapies 1
• This explains why some patients maintain intrathecal antibody production despite peripheral B-cell depletion

3. Emerging Therapeutic Target

CD19 CAR-T cell therapy represents a novel approach:

• Targets CD19+ B cells more comprehensively than anti-CD20 antibodies 7
• In two progressive MS patients, CD19 CAR-T cells showed acceptable safety profiles with no immune effector cell-associated neurotoxicity syndrome (ICANS) despite CSF penetration 7
• Intrathecal antibody production decreased notably through day 64 post-infusion 7
• This approach may address compartmentalized CNS inflammation in progressive MS 8

What CD19 Levels Do NOT Predict

Critical limitations based on evidence:

• CD19+ B-cell counts do NOT predict:

  • Likelihood of progressive disease course 3
  • EDSS progression 3
  • Conversion from CIS to clinically definite MS 3
  • Relapse rate in untreated patients 3

• Better predictors of disease progression include:

  • Age at baseline (higher age → progressive course) 3
  • Number of T2 MRI lesions (≥9 lesions → faster conversion to CDMS) 3
  • Brain and spinal cord atrophy measures 9

Practical Clinical Algorithm

For Patients Starting Anti-CD20 Therapy:

1. Measure baseline CD19+ B-cell count before first infusion
2. Higher baseline counts (>upper quartile) → consider standard or slightly higher initial dosing
3. Recheck CD19 at 6 months:
   • If depleted (<1% of lymphocytes) → extend to 6-9 month intervals
   • If not depleted (>2% of lymphocytes) → maintain 6-month schedule or increase dose
4. Recheck at 12 months and correlate with MRI activity:
   • Persistent CD19+ cells + new MRI lesions → shorten interval or increase dose
   • Complete depletion + no MRI activity → consider extending intervals

Common Pitfalls:

• Do not use CD19 counts for MS diagnosis - they lack sensitivity and specificity 3
• Do not assume fixed dosing schedules are optimal - repopulation kinetics vary 3-fold between individuals 5
• Remember that CD138+ plasma cells producing intrathecal antibodies are CD19-negative and not captured by CD19 monitoring 1
• African American patients may have different B-cell dynamics requiring individualized interpretation 2